NO20014491D0 - Fremgangsmåte - Google Patents

Fremgangsmåte

Info

Publication number
NO20014491D0
NO20014491D0 NO20014491A NO20014491A NO20014491D0 NO 20014491 D0 NO20014491 D0 NO 20014491D0 NO 20014491 A NO20014491 A NO 20014491A NO 20014491 A NO20014491 A NO 20014491A NO 20014491 D0 NO20014491 D0 NO 20014491D0
Authority
NO
Norway
Prior art keywords
cell
antigenic molecule
stimulating
approach
immune response
Prior art date
Application number
NO20014491A
Other languages
English (en)
Other versions
NO20014491L (no
NO331101B1 (no
Inventor
Kristian Berg
Torunn E Tjelle
Anders Hoegsetm
Lina Prasmickaite
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of NO20014491D0 publication Critical patent/NO20014491D0/no
Publication of NO20014491L publication Critical patent/NO20014491L/no
Publication of NO331101B1 publication Critical patent/NO331101B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20014491A 1999-03-15 2001-09-14 In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet. NO331101B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9905911.5A GB9905911D0 (en) 1999-03-15 1999-03-15 Method
PCT/GB2000/000903 WO2000054802A2 (en) 1999-03-15 2000-03-10 Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization

Publications (3)

Publication Number Publication Date
NO20014491D0 true NO20014491D0 (no) 2001-09-14
NO20014491L NO20014491L (no) 2001-11-14
NO331101B1 NO331101B1 (no) 2011-10-03

Family

ID=10849643

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014491A NO331101B1 (no) 1999-03-15 2001-09-14 In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet.

Country Status (19)

Country Link
US (2) US8216587B1 (no)
EP (1) EP1223973B1 (no)
JP (1) JP4922490B2 (no)
KR (1) KR100769113B1 (no)
CN (1) CN100379450C (no)
AT (1) ATE419866T1 (no)
AU (1) AU771990B2 (no)
CA (1) CA2367357C (no)
CZ (1) CZ299370B6 (no)
DE (1) DE60041347D1 (no)
DK (1) DK1223973T3 (no)
ES (1) ES2319255T3 (no)
GB (1) GB9905911D0 (no)
HU (1) HU227604B1 (no)
MX (1) MXPA01009316A (no)
NO (1) NO331101B1 (no)
NZ (1) NZ514228A (no)
PL (1) PL208221B1 (no)
WO (1) WO2000054802A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044396A1 (en) * 2000-11-29 2002-06-06 Pci Biotech As Photochemical internalization for delivery of molecules into the cytosol
KR20030074633A (ko) * 2000-11-29 2003-09-19 피씨아이 바이오테크 에이에스 사이토졸 내로의 바이러스 매개된 분자 전달을 위한광화학적 내부이행
AU2002250034A1 (en) * 2001-02-08 2002-08-19 Sequitur, Inc. Methods of light activated release 0f ligands from endosomes
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
EP2221377B2 (en) 2002-02-01 2017-05-17 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
MX2009003764A (es) * 2006-10-04 2009-04-22 Janssen Pharmaceutica Nv Preparaciones de celulas presentadoras de antigeno artificiales y su uso en terapias celulares.
GB0811955D0 (en) 2008-06-30 2008-07-30 Pci Biotech As Method
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
GB0914286D0 (en) * 2009-08-14 2009-09-30 Pci Biotech As Method
GB201208548D0 (en) * 2012-05-15 2012-06-27 Pci Biotech As Compound and method
CA2906279A1 (en) * 2013-03-15 2014-09-18 Pci Biotech As A method of generating antigen presenting cells using photochemical internalisation
EP3038619B1 (en) * 2013-08-28 2023-10-04 PCI Biotech AS Compound and method for vaccination and immunisation
GB2517707B (en) * 2013-08-28 2020-09-02 Pci Biotech As A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen
WO2015028575A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Immunisation method by photochemical internalisation
AU2014390262B2 (en) * 2014-04-11 2020-11-26 Pci Biotech As Method of treating melanoma
AU2015308345B9 (en) 2014-08-28 2020-12-24 Pci Biotech As Compound and method
GB201415250D0 (en) * 2014-08-28 2014-10-15 Pci Biotech As Compound and method
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
RU2019109682A (ru) 2016-10-14 2020-11-16 ПиСиАй БИОТЕК АС Лечение холангиокарциномы с применением tpcs-2-индуцированной фотохимической интернализации гемцитабина
CN107029236B (zh) * 2017-04-18 2020-04-10 中国医学科学院生物医学工程研究所 一种吲哚菁绿自组装纳米疫苗及制备方法
CN107217041B (zh) * 2017-07-11 2020-05-15 深圳华云生物技术有限公司 具有高抗原呈递的dc细胞和抗原特异性t细胞及其制备方法和应用
GB201718631D0 (en) 2017-11-10 2017-12-27 Pci Biotech As Method
EP3823668A1 (en) 2018-07-16 2021-05-26 DCPrime B.V. A combination product for use in tumor vaccination
WO2020217226A1 (en) 2019-04-25 2020-10-29 Dcprime B.V. Methods of tumor vaccination
EP4125943A1 (en) 2020-03-27 2023-02-08 Mendus B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
GB202115451D0 (en) 2021-10-27 2021-12-08 Pci Biotech As Method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
IL132066A (en) * 1997-05-07 2008-06-05 Quadra Logic Tech Inc History of monohydrobenzoporphyrin-bite (ethylene glycol) tetraalkyl esters as light-acting agents
WO2002044396A1 (en) 2000-11-29 2002-06-06 Pci Biotech As Photochemical internalization for delivery of molecules into the cytosol
GB201208548D0 (en) 2012-05-15 2012-06-27 Pci Biotech As Compound and method
EP3038619B1 (en) 2013-08-28 2023-10-04 PCI Biotech AS Compound and method for vaccination and immunisation

Also Published As

Publication number Publication date
EP1223973B1 (en) 2009-01-07
EP1223973A2 (en) 2002-07-24
PL355015A1 (en) 2004-03-22
JP2002541072A (ja) 2002-12-03
PL208221B1 (pl) 2011-03-31
US20130330363A1 (en) 2013-12-12
JP4922490B2 (ja) 2012-04-25
CZ299370B6 (cs) 2008-07-09
AU771990B2 (en) 2004-04-08
CA2367357C (en) 2015-01-06
WO2000054802A2 (en) 2000-09-21
GB9905911D0 (en) 1999-05-05
CN1376073A (zh) 2002-10-23
KR20010110664A (ko) 2001-12-13
CA2367357A1 (en) 2000-09-21
ES2319255T3 (es) 2009-05-06
NZ514228A (en) 2004-01-30
NO20014491L (no) 2001-11-14
KR100769113B1 (ko) 2007-10-22
CZ20013328A3 (cs) 2002-03-13
WO2000054802A3 (en) 2002-05-10
CN100379450C (zh) 2008-04-09
HUP0202441A3 (en) 2004-07-28
US9737594B2 (en) 2017-08-22
US8216587B1 (en) 2012-07-10
DK1223973T3 (da) 2009-05-04
MXPA01009316A (es) 2003-07-14
DE60041347D1 (de) 2009-02-26
HU227604B1 (en) 2011-09-28
AU3177100A (en) 2000-10-04
HUP0202441A2 (en) 2002-10-28
NO331101B1 (no) 2011-10-03
ATE419866T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
NO20014491D0 (no) Fremgangsmåte
CY1117551T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
ATE163195T1 (de) Lösliche liganden für cd40
NL190624C (nl) Gasafdichtingsinrichting voor een as.
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE529130T1 (de) Trockenformulierung für transkutane immunisierung
BR0015611A (pt) Processo de limpeza que utiliza ondas ultra-sÈnicas
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
NO921239D0 (no) Fremgangsmaate for fremstilling av overflate-modifiserte faste substrater
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
DE69834921D1 (de) Antigen enthaltende zusammensetzung, die zusätzlich derivatisierte monoglyceride oder diglyceride als adjuvantien enthält
DE69130709T2 (de) Gezielte immunostimulierung mit bispezifischen stoffen
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
EA199900069A1 (ru) Вакцинная композиция против малярии
DE602004020189D1 (de) Adjuvante influenza-vakzine
EA200000349A1 (ru) Способ лечения оппозиционного расстройства
DK0985675T3 (da) Hydrosilaniseringsfremgangsmåde med höjt udbytte
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
ES2175798T3 (es) Cd8 como un inhibidor del sistema inmunitario celular.
NO890046L (no) Disubstituerte pyridiner.
DE68915112T2 (de) Spiro-isochinolin-pyrrolidin-tetrone und Analoge davon, verwendbar als Aldosereduktase-Inhibitoren.
DE602005007177D1 (de) Komplexe mit adjuvanter wirkung
DK1037642T3 (da) Modificerede polysaccharider med ændret biologisk genkendelse
DE59611293D1 (de) Protein mit dnase-aktivität
DE69123252T2 (de) Kreuzreaktive immunisierung gegen influenza

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees